Market Place
Sourcing Support
Coya Publishes Longitudinal COYA 302 ALS Data: Outcomes &
09 Apr 2026 //
PHARMIWEB
Coya Therapeutics Appoints Mark H. Pavao as Independent Director
02 Apr 2026 //
PHARMIWEB
Coya Therapeutics: T-Cell Dysfunction in Frontotemporal Dementia
18 Mar 2026 //
PHARMIWEB
Coya Therapeutics Hosts ALS Drug Development Webinar
10 Feb 2026 //
BUSINESSWIRE
Coya Therapeutics Announces $11.1 Million Private Placement
30 Jan 2026 //
BUSINESSWIRE
Coya Therapeutics Reveals Study Results Showing Treg Boost
08 Jan 2026 //
PHARMIWEB
COYA Therapeutics` COYA 302 (IND) Accepted By U.S. FDA
05 Jan 2026 //
BUSINESSWIRE
COYA Therapeutics Gets Canada Approval For COYA 302 Trial
23 Dec 2025 //
BUSINESSWIRE
Coya Therapeutics Begins COYA 302 Dosing in ALSTARS Trial
09 Dec 2025 //
PRESS RELEASE
Coya Therapeutics To Join Investor & Clinical Trials Conferences
25 Nov 2025 //
BUSINESSWIRE
Coya Reports Potent Anti-Inflammatory Efficacy of COYA 303
04 Nov 2025 //
BUSINESSWIRE
Coya Therapeutics Completes $23M Public Stock Offering
27 Oct 2025 //
BUSINESS WIRE
Coya Exec Barvin Aims To Eradicate Genetic ALS And FTD
27 Oct 2025 //
BIOSPACE
Coya Therapeutics Prices $20M Upsized Public Stock Offering
24 Oct 2025 //
BUSINESSWIRE
Coya Therapeutics Plans Public Stock Offering
23 Oct 2025 //
BUSINESSWIRE
Coya Completes Enrollment in IL-2 + CTLA4-Ig Dementia Study
29 Sep 2025 //
PR NEWSWIRE
Coya Therapeutics Initiates Alstars Trial For Coya 302 In ALS
22 Sep 2025 //
PR NEWSWIRE
Coya Therapeutics` COYA 303 Demonstrates CNS Anti-inflammatory
16 Sep 2025 //
PR NEWSWIRE
Coya Therapeutics to Present at September Investor Conferences
03 Sep 2025 //
PR NEWSWIRE
Another biotech hit with FDA delay for ALS asset
18 Aug 2025 //
FIERCE BIOTECH
FDA Delays Impact Clinical Trial Launch Decisions
30 Jul 2025 //
FIERCE BIOTECH
Coya Therapeutics to Join Virtual Biotech Conference, July 2025
22 Jul 2025 //
BUSINESSWIRE
Coya Therapeutics to Present at iAccess Alpha Virtual Conference
18 Jun 2025 //
BUSINESSWIRE
Coya Gets Patent for Liquid Form of Aldesleukin
02 Jun 2025 //
BUSINESSWIRE
Coya Therapeutics at H.C. Wainwright BioConnect Conference
16 May 2025 //
BUSINESSWIRE
Coya Therapeutics Reports Q1 Financials and Corporate Update
13 May 2025 //
BUSINESSWIRE
Coya Therapeutics to Join Two May 2025 Conferences
08 May 2025 //
BUSINESSWIRE
Coya Therapeutics reports positive results in study on dementia
24 Apr 2025 //
BUSINESSWIRE
Coya Reports Positive Results in Frontotemporal Dementia Study
24 Apr 2025 //
ACCESSWIRE
Coya Publishes Data on COYA 303 Boosting Treg Cell Function
21 Apr 2025 //
BUSINESSWIRE
Coya Therapeutics to Present at ADPD 2025 Conference in Vienna
01 Apr 2025 //
BUSINESSWIRE
Coya To Join BTIG KOL Call On GLP-1 Agonists For AD Treatment
25 Feb 2025 //
BUSINESSWIRE
Coya Expands Pipeline With COYA 303 For Inflammatory Diseases
21 Jan 2025 //
BUSINESSWIRE
Coya Therapeutics Updates Phase 1 Study of IL-2 + CTLA4-Ig in FTD
18 Dec 2024 //
BUSINESSWIRE
Coya Therapeutics to Join Chat at Evercore HealthCONx Conference
25 Nov 2024 //
BUSINESSWIRE
Coya Therapeutics CEO Dr. Arun Issues Letter to Stockholders
19 Nov 2024 //
BUSINESSWIRE
Coya Therapeutics Provides Q3 2024 Update & Financial Results
06 Nov 2024 //
BUSINESSWIRE
Coya Therapeutics Closes $10M Private Placement
23 Oct 2024 //
BUSINESSWIRE
Coya Therapeutics Announces $10.0 Million Private Placement
22 Oct 2024 //
BUSINESSWIRE
Coya Therapeutics CEO Howard Berman Selected For PharmaVoice 100
08 Oct 2024 //
BUSINESSWIRE
Coya Therapeutics Joins Chardan`s Genetic Medicines Conference
24 Sep 2024 //
BUSINESSWIRE
Coya Therapeutics Reports COYA 302 Preclinical Data t of PD
16 Sep 2024 //
BUSINESSWIRE
Coya Therapeutics Promotes Arun Swaminathan To CEO Effective November 1st
19 Aug 2024 //
BUSINESSWIRE
Coya Therapeutics Reports Q2 2024 Results And Provides Corporate Update
12 Aug 2024 //
BUSINESSWIRE
Coya Therapeutics To Present Alzheimer`s Study Results At CTAD24
02 Aug 2024 //
BUSINESSWIRE
Coya Presents Updated ALS Biomarker Data
26 Apr 2024 //
BUSINESSWIRE
Coya Issues Letter to Stockholders Highlighting Expansion of COYA 302
21 Feb 2024 //
BUSINESSWIRE
Coya Therapeutics to Participate in Chardan Biotech Leadership Call Series
18 Jan 2024 //
BUSINESSWIRE
Coya Announces Successful Pre-IND aMeetings to Advance COYA 302
05 Jan 2024 //
BUSINESSWIRE
Coya Presents Experimental Data Supporting the Mechanism of Action of COYA 302
05 Oct 2023 //
BUSINESSWIRE
Coya Announces Publication of Potential Novel Blood Biomarker Data in (ALS)
31 Aug 2023 //
BUSINESSWIRE
Coya To Present Novel Proof of Concept Exosome Modification Technology
25 Aug 2023 //
BUSINESSWIRE
Coya Therapeutics Appoints Dr. Fred Grossman, to President and CMO
05 Jul 2023 //
BUSINESSWIRE
Coya Therapeutics Appoints Dr. Michelle Frazier as Senior Vice President
14 Jun 2023 //
BUSINESSWIRE
Coya Therapeutics’ CEO Dr. Howard Berman’s Letter to Stockholders
12 Jun 2023 //
BUSINESSWIRE
Coya Therapeutics Reports Additional Blood Biomarker and Brain Imaging Data
07 Jun 2023 //
BUSINESSWIRE
Coya Therapeutics Strengthens SAB with the Addition of Dr. Guillaume Dorothée
05 Jun 2023 //
BUSINESSWIRE
Coya to Present Additional Biomarker and Brain Imaging Data for COYA 301
22 May 2023 //
BUSINESSWIRE
Coya Therapeutics, Inc. Provides Business Update and Reports Q1 2023
10 May 2023 //
BUSINESSWIRE
Coya Announces Positive Results from Academic Study for COYA 302
21 Mar 2023 //
BUSINESSWIRE
